Used in targeted drug delivery systems, this compound is designed to enhance the solubility and bioavailability of therapeutic agents. It is particularly valuable in the development of prodrugs, where the PEG4 linker improves pharmacokinetics. The thalidomide moiety allows for targeted degradation of specific proteins via the ubiquitin-proteasome pathway, making it useful in cancer therapies and research involving protein knockdown. Its application extends to the study of cereblon-binding drugs, aiding in the development of treatments for multiple myeloma and other malignancies. Additionally, it serves as a versatile tool in bioconjugation and chemical biology for creating stable and functionalized biomolecules.